CancerNetwork® spoke with Dr. Peter Schmid about the KEYNOTE-522 trial.
Dr. Rebecca Dent, oncologist at the National Cancer Center, Singapore, discusses the rationale for immunotherapy in early-stage breast cancer.
Dr. Leisha Emens of the University of Pittsburgh Medical Center's Hillman Cancer Center discusses the overall survival in the KATE2 study.
Adding the immunotherapy pembrolizumab to neoadjuvant chemotherapy improved the pathological complete response rate in patients with early triple-negative breast cancer, according to findings of a study presented at ESMO.
Two studies from ESMO have potentially found treatments which can improve survival in HR-positive breast cancer.
The combo showed improvement in disease-free survival over tamoxifen in premenopausal patients with hormone receptor (HR)-positive early breast cancer.
Researchers compared the cost effectiveness of two durations of trastuzumab in HER2+ breast cancer patients.
The SOLAR-1 trial tested whether the PI3K inhibitor alpelisib improved outcomes in HR+, HER2− breast cancer patients.
A subgroup analysis of Short-HER looked at the differences in 5-year DFS rates for 9 weeks vs 1 year of trastuzumab for HER2+ breast cancer patients.
Researchers tested whether combining chemotherapy with immunotherapy would offer improved survival for patients with triple-negative breast cancer.